Tamer Soror1,2, György Kovács3, Nina Seibold3, Corinna Melchert3, Kristin Baumann4, Eike Wenzel5, Suzana Stojanovic-Rundic6. 1. Interdisciplinary Brachytherapy Unit, University of Luebeck/UKSH-CL, Ratzeburger Allee 160, 23538, Luebeck, Germany. tamer.soror@uksh.de. 2. National Cancer Institute (NCI), Radiation Oncology Department, Cairo University, Cairo, Egypt. tamer.soror@uksh.de. 3. Interdisciplinary Brachytherapy Unit, University of Luebeck/UKSH-CL, Ratzeburger Allee 160, 23538, Luebeck, Germany. 4. Clinic for Gynecology and Obstetrics, University of Luebeck/UKSH-CL, Luebeck, Germany. 5. Clinic for Plastic Surgery, University of Luebeck/UKSH-CL, Luebeck, Germany. 6. Institute for Oncology and Radiology (IORS), Medical School University of Belgrade, Belgrade, Serbia.
Abstract
BACKGROUND: Patients with early-stage breast cancer can benefit from adjuvant accelerated partial breast irradiation (APBI) following breast-conserving surgery (BCS). This work reports on cosmetic results following APBI using multicatheter high-dose-rate interstitial brachytherapy (HDR-IBT). PATIENTS AND METHODS: Between 2006 and 2014, 114 patients received adjuvant APBI using multicatheter HDR-IBT. For each patient, two photographs were analyzed: the first was taken after surgery (baseline image) and the second at the last follow-up visit. Cosmesis was assessed by a multigender multidisciplinary team using the Harvard Breast Cosmesis Scale. Dose-volume histogram (DVH) parameters and the observed cosmetic results were investigated for potential correlations. RESULTS: The median follow-up period was 3.5 years (range 0.6-8.5 years). The final cosmetic scores were 30% excellent, 52% good, 14.5% fair, and 3.5% poor. Comparing the baseline and follow-up photographs, 59.6% of patients had the same score, 36% had a better final score, and 4.4% had a worse final score. Only lower target dose nonuniformity ratio (DNR) values (0.3 vs. 0.26; p = 0.009) were significantly associated with improved cosmetic outcome vs. same/worse cosmesis. CONCLUSION: APBI using multicatheter HDR-IBT adjuvant to BCS results in favorable final cosmesis. Deterioration in breast cosmesis occurs in less than 5% of patients. The final breast cosmetic outcome in patients treated with BCS and APBI using multicatheter HDR-IBT is influenced primarily by the cosmetic result of the surgery. A lower DNR value is significantly associated with a better cosmetic outcome.
BACKGROUND:Patients with early-stage breast cancer can benefit from adjuvant accelerated partial breast irradiation (APBI) following breast-conserving surgery (BCS). This work reports on cosmetic results following APBI using multicatheter high-dose-rate interstitial brachytherapy (HDR-IBT). PATIENTS AND METHODS: Between 2006 and 2014, 114 patients received adjuvant APBI using multicatheter HDR-IBT. For each patient, two photographs were analyzed: the first was taken after surgery (baseline image) and the second at the last follow-up visit. Cosmesis was assessed by a multigender multidisciplinary team using the Harvard Breast Cosmesis Scale. Dose-volume histogram (DVH) parameters and the observed cosmetic results were investigated for potential correlations. RESULTS: The median follow-up period was 3.5 years (range 0.6-8.5 years). The final cosmetic scores were 30% excellent, 52% good, 14.5% fair, and 3.5% poor. Comparing the baseline and follow-up photographs, 59.6% of patients had the same score, 36% had a better final score, and 4.4% had a worse final score. Only lower target dose nonuniformity ratio (DNR) values (0.3 vs. 0.26; p = 0.009) were significantly associated with improved cosmetic outcome vs. same/worse cosmesis. CONCLUSION: APBI using multicatheter HDR-IBT adjuvant to BCS results in favorable final cosmesis. Deterioration in breast cosmesis occurs in less than 5% of patients. The final breast cosmetic outcome in patients treated with BCS and APBI using multicatheter HDR-IBT is influenced primarily by the cosmetic result of the surgery. A lower DNR value is significantly associated with a better cosmetic outcome.
Entities:
Keywords:
Breast cancer; Breast-conserving surgery; Photographs; Survival; Toxicity
Authors: Saskia Litière; Gustavo Werutsky; Ian S Fentiman; Emiel Rutgers; Marie-Rose Christiaens; Erik Van Limbergen; Margreet H A Baaijens; Jan Bogaerts; Harry Bartelink Journal: Lancet Oncol Date: 2012-02-27 Impact factor: 41.316
Authors: A J Khan; Douglas Arthur; F Vicini; P Beitsch; H Kuerer; S Goyal; Maureen Lyden; B G Haffty Journal: Ann Surg Oncol Date: 2011-11-23 Impact factor: 5.344
Authors: Ivo A Olivotto; Timothy J Whelan; Sameer Parpia; Do-Hoon Kim; Tanya Berrang; Pauline T Truong; Iwa Kong; Brandy Cochrane; Alan Nichol; Isabelle Roy; Isabelle Germain; Mohamed Akra; Melanie Reed; Anthony Fyles; Theresa Trotter; Francisco Perera; Wayne Beckham; Mark N Levine; Jim A Julian Journal: J Clin Oncol Date: 2013-07-08 Impact factor: 44.544
Authors: Csaba Polgár; Tibor Major; János Fodor; Zoltán Sulyok; András Somogyi; Katalin Lövey; György Németh; Miklós Kásler Journal: Radiother Oncol Date: 2010-02-22 Impact factor: 6.280
Authors: Vratislav Strnad; Guido Hildebrandt; Richard Pötter; Josef Hammer; Marion Hindemith; Alexandra Resch; Kurt Spiegl; Michael Lotter; Wolfgang Uter; Mayada Bani; Rolf-Dieter Kortmann; Matthias W Beckmann; Rainer Fietkau; Oliver J Ott Journal: Int J Radiat Oncol Biol Phys Date: 2010-06-03 Impact factor: 7.038
Authors: Anna-Maria Roth; Daniela Kauer-Dorner; Alexandra Resch; Andreas Schmid; Marc Thill; Peter Niehoff; Corinna Melchert; Daniel Berger; György Kovács Journal: Brachytherapy Date: 2014 Jul-Aug Impact factor: 2.362
Authors: Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum Journal: Lancet Date: 2013-11-11 Impact factor: 79.321
Authors: Cecilia Dahlbäck; Jenny Heiman Ullmark; Martin Rehn; Anita Ringberg; Jonas Manjer Journal: Breast Cancer Res Treat Date: 2017-05-23 Impact factor: 4.872
Authors: András Herein; Gábor Stelczer; Csilla Pesznyák; Georgina Fröhlich; Viktor Smanykó; Norbert Mészáros; Csaba Polgár; Tibor Major Journal: Radiol Oncol Date: 2021-03-25 Impact factor: 2.991
Authors: András Herein; Gábor Stelczer; Csilla Pesznyák; Georgina Fröhlich; Viktor Smanykó; Norbert Mészáros; Csaba Polgár; Zoltán Takácsi-Nagy; Tibor Major Journal: Rep Pract Oncol Radiother Date: 2022-03-22